FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316170836> ?p ?o ?g. }

• W2316170836 endingPage "826" @default.
• W2316170836 startingPage "825" @default.
• W2316170836 abstract "Late-onset cytomegalovirus (CMV) disease, defined as CMV disease occurring after 3 months posttransplant is a significant complication with the use of prophylaxis, particularly in R−/D+ patients (1–4). The incidence of late-onset CMV disease in the valganciclovir era is substantially higher with prophylaxis than with preemptive therapy (5). The risk of late-occurring CMV disease is also higher with a more completely suppressive antiviral regimen (6). Although precise reasons for these observations are not known, preemptive therapy by its inherent design allows controlled viral replication to occur and this antigen exposure could potentially result in enhancement of CMV-specific immunity critical in the long-term control of virus (7). A limited number of studies have assessed CMV-specific immunity in R−/D+ patients receiving prophylaxis. CD8+ T-cell interferon-γ response to pp65 and immediate early (IE)-1 antigens was documented in all 17 R−/D+ liver transplant recipients; however, neither predicted late-onset CMV disease (8). Although viremia level more than 1000 copies/mL correlated with current CMV disease, viral loads performed 2 to 4 weeks prior were not predictive of disease (8). Assessment of CD8+ T cells using 21-peptide pool Quantiferon assay documented detectable responses in 35% of the R+ or D+ patients who had received prophylaxis (9). Among patients with CMV disease, 83% (15/18) had negative responses before the onset of CMV disease (9). In R−/D+ subgroup, the incidence of positive responses was 20%. CMV disease occurred in 31% of patients; 14% in patients with positive responses and 36% in those with negative responses (P=0.39). Taken together, these data document a variable and often a low rate of detectable CMV-specific immune responses in high-risk patients receiving prophylaxis. Further, these responses did not consistently predict late-onset CMV disease. BenMarzouk-Hidalgo et al. (10) showed that CMV-specific immunity developed a median of 12 weeks posttransplant in all 21 R−/D+ transplant recipients who received preemptive therapy with valganciclovir. Viral loads were lower after the acquisition of antiviral immunity when compared with before, and the episodes of viremia after the development of CMV-specific immunity resolved spontaneously; none developed late-onset CMV disease at 12 months. Given that there was no comparator or control group with CMV disease, it cannot be incontrovertibly concluded that the immune responses were necessarily protective, only that they were detectable in a cohort who did not develop CMV disease. Although the use of T-cell-depleting agent had no effect on CMV-specific immunity in a previous study (11), the findings of this study must be interpreted in context of the fact that none of the patients received T-cell-depleting agent–based immunosuppression (10). Finally, the effect of controlled viral replication after the development of CMV-specific responses on outcomes other than late-onset CMV disease is not known. Nevertheless, the provocative findings of this study demonstrate that such a response is frequently detectable following preemptive therapy with potentially beneficial immunologic effects against CMV disease. That exposure to the virus facilitates CMV-specific immune reconstitution has also been shown in another study (11). CMV-specific immune responses remained undetectable in 13 R−/D+ patients throughout the period of prophylaxis (11). Only 5 of the 13 patients gained immune reconstitution by 360 days and in all, viremia preceded the appearance of detectable immunity. On the other hand, R+ patients who received preemptive therapy displayed progressive increase in CMV immunity after 60 days with fully recovered responses in a majority by 180 to 360 days. CMV viremia even at low level boosted immune recovery in R+ patients. These data suggest that (i) low-grade viremia enhanced immunity in R+ patients receiving preemptive therapy, (ii) viral suppression in R− patients receiving prophylaxis may impair immune priming, and (iii) virus exposure contributed to T-cell recovery in R− patients who ultimately gained detectable CMV-specific T-cell responses. Although interferon-γ production is important, antigen-specific CD8+ T cells are functionally heterogenous and multifunctional T cells are superior surrogates of antiviral host defense than single cytokine assessments of T cells (12, 13). Generation of multifunctional CMV-specific T-cell immunity was more robust in D+ or R+ compared with D− or R+ allogeneic stem-cell transplant recipients and correlated with reduced duration and lower requirement of recurrent antiviral therapy (12). Prevention of late-onset CMV disease has proven challenging and is hampered by the fact that its pathophysiologic basis is poorly understood and surrogate markers to identify patients at risk have not been identified. Further attempts at advancing the field must also identify the specific types of antiviral responses that are able to control viral replication and prevent late-onset CMV disease. Finally, future studies should determine whether proposed immunologic benefits of controlled viral replication have a salutary effect on indirect outcomes related to CMV." @default.
• W2316170836 created "2016-06-24" @default.
• W2316170836 creator A5079624082 @default.
• W2316170836 date "2011-04-27" @default.
• W2316170836 modified "2023-10-18" @default.
• W2316170836 title "Unraveling the Biologic Basis of Late-Onset Cytomegalovirus Disease in High-Risk Organ Transplant Recipients" @default.
• W2316170836 cites W1972991400 @default.
• W2316170836 cites W1978937860 @default.
• W2316170836 cites W2041691002 @default.
• W2316170836 cites W2065520476 @default.
• W2316170836 cites W2076856323 @default.
• W2316170836 cites W2079627032 @default.
• W2316170836 cites W2087762810 @default.
• W2316170836 cites W2090071293 @default.
• W2316170836 cites W2091756255 @default.
• W2316170836 cites W2127638351 @default.
• W2316170836 cites W2132312965 @default.
• W2316170836 cites W2330054845 @default.
• W2316170836 doi "https://doi.org/10.1097/tp.0b013e3182126eb9" @default.
• W2316170836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21372754" @default.
• W2316170836 hasPublicationYear "2011" @default.
• W2316170836 type Work @default.
• W2316170836 sameAs 2316170836 @default.
• W2316170836 citedByCount "4" @default.
• W2316170836 countsByYear W23161708362012 @default.
• W2316170836 countsByYear W23161708362014 @default.
• W2316170836 crossrefType "journal-article" @default.
• W2316170836 hasAuthorship W2316170836A5079624082 @default.
• W2316170836 hasBestOaLocation W23161708361 @default.
• W2316170836 hasConcept C126322002 @default.
• W2316170836 hasConcept C203014093 @default.
• W2316170836 hasConcept C2522874641 @default.
• W2316170836 hasConcept C2776185481 @default.
• W2316170836 hasConcept C2776317777 @default.
• W2316170836 hasConcept C2776409557 @default.
• W2316170836 hasConcept C2777662283 @default.
• W2316170836 hasConcept C2777732132 @default.
• W2316170836 hasConcept C2777965375 @default.
• W2316170836 hasConcept C2779134260 @default.
• W2316170836 hasConcept C2779820661 @default.
• W2316170836 hasConcept C2780727368 @default.
• W2316170836 hasConcept C71924100 @default.
• W2316170836 hasConceptScore W2316170836C126322002 @default.
• W2316170836 hasConceptScore W2316170836C203014093 @default.
• W2316170836 hasConceptScore W2316170836C2522874641 @default.
• W2316170836 hasConceptScore W2316170836C2776185481 @default.
• W2316170836 hasConceptScore W2316170836C2776317777 @default.
• W2316170836 hasConceptScore W2316170836C2776409557 @default.
• W2316170836 hasConceptScore W2316170836C2777662283 @default.
• W2316170836 hasConceptScore W2316170836C2777732132 @default.
• W2316170836 hasConceptScore W2316170836C2777965375 @default.
• W2316170836 hasConceptScore W2316170836C2779134260 @default.
• W2316170836 hasConceptScore W2316170836C2779820661 @default.
• W2316170836 hasConceptScore W2316170836C2780727368 @default.
• W2316170836 hasConceptScore W2316170836C71924100 @default.
• W2316170836 hasIssue "8" @default.
• W2316170836 hasLocation W23161708361 @default.
• W2316170836 hasLocation W23161708362 @default.
• W2316170836 hasOpenAccess W2316170836 @default.
• W2316170836 hasPrimaryLocation W23161708361 @default.
• W2316170836 hasRelatedWork W1987968693 @default.
• W2316170836 hasRelatedWork W2032585117 @default.
• W2316170836 hasRelatedWork W2036501459 @default.
• W2316170836 hasRelatedWork W2102478653 @default.
• W2316170836 hasRelatedWork W2122069343 @default.
• W2316170836 hasRelatedWork W2122221406 @default.
• W2316170836 hasRelatedWork W2159829581 @default.
• W2316170836 hasRelatedWork W2397592018 @default.
• W2316170836 hasRelatedWork W3047369617 @default.
• W2316170836 hasRelatedWork W4365518106 @default.
• W2316170836 hasVolume "91" @default.
• W2316170836 isParatext "false" @default.
• W2316170836 isRetracted "false" @default.
• W2316170836 magId "2316170836" @default.
• W2316170836 workType "article" @default.